Trends in DRM prevalence
The initial samples for 2,107 patients collected over 5 years were
assessed. The overall prevalence of DRMs, including all DRM types
(low-level, intermediate, and high-level mutations), declined from
39.4% before 2018 to 31.6% in 2022 (Figure 3). The prevalence of
high-level resistance mutations, which are more clinically significant,
also declined from 16.7% to 7.7% between 2018 and 2022. The DRM trends
in NRTIs and INSTIs decreased from 14.5% to 6.4% and 8.0% to 1.7%,
respectively, whereas NNRTIs showed a lateral trend from 27.7% to
26.3%. The DRM trends in PIs declined steadily from 39.4% to 31.6%.